Last updated: July 11, 2026

Application No. 19/418,900

Untitled Application

Unknown

Filed

1600

Priority

Oct 31, 2017 — provisional 62/579,234 +2 more

Examiner

SANG, HONG

Art Unit

1646

Tech Center

Janssen Biotech, Inc.

Assignee

Janssen Pharmaceuticals Inc.

OA Round

1 (Non-Final)

This examiner grants 55% of cases after interview

— +62.2% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 920 resolved cases, 2023–2026

Examiner Intelligence

SANG, HONG View full profile →

Grants 55% of resolved cases

Career Allowance Rate

504 granted / 920 resolved

-5.2% vs TC avg

Strong +62% interview lift

Without

With

+62.2%

Interview Lift

resolved cases with interview

Typical timeline

3y 5m

Avg Prosecution

40 currently pending

Career history

962

Total Applications

across all art units

Statute-Specific Performance

§101

0.6%

-39.4% vs TC avg

§103

38.3%

-1.7% vs TC avg

§102

12.8%

-27.2% vs TC avg

§112

16.5%

-23.5% vs TC avg

Black line = Tech Center average estimate • Based on career data from 920 resolved cases

Prosecution Timeline

1600

Application Filed

Mar 30, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/783,506

Patent 12674002

MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING

4y 1m to grant Granted Jul 07, 2026

19/064,618

Patent 12655391

MODIFIED K562 FEEDER CELL LINE EXPRESSING FACTORS THAT ENHANCE THE ACTIVATION AND PROLIFERATION OF NATURAL KILLER CELLS AND A METHOD FOR ITS PRODUCTION

1y 3m to grant Granted Jun 16, 2026

18/181,640

Patent 12636362

Human Anti-VEGFR-2/KDR Antibodies

3y 2m to grant Granted May 26, 2026

17/355,756

Patent 12630632

BISPECIFIC HER2 AND CD3 BINDING MOLECULES

4y 11m to grant Granted May 19, 2026

17/824,266

Patent 12631639

METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS

3y 12m to grant Granted May 19, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

55%

Grant Probability

99%

With Interview (+62.2%)

3y 5m

Median Time to Grant

Low

PTA Risk

Based on 920 resolved cases by this examiner. Grant probability derived from career allowance rate.